• STUDIES
    Participation is open to worldwide institutions.
    Read More
  • MEETINGS
    Since 1998, an Annual Meeting of the IELSG investigators has been regularly held.
    Read More
  • NEWSLETTER
    The IELSG Newsletter informs about studies, meetings and other research activities.
    Read More
  • PUBLICATIONS
    The results are presented to major congresses and published into peer-reviewed journals.
    Read More

Fighting cancer through research. You can support us by making a donation, however large or small.

Support Us

LATEST NEWS

  • We have moved

    NEW ADDRESS (as of 25.07.2022)
    IELSG Headquarters
    Foundation for the Institute of Oncology Research (IOR)
    Via Vincenzo Vela, 6
    CH-6500 Bellinzona
    Phone + 41 58 666 73 21
    ielsg@ior.usi.ch

  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
    Reference Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Link
    Author(s) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators.
    Study IELSG32

ONGOING STUDIES

  • IELSG49
    IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
  • IELSG44
    IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
  • IELSG47 Study
    MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

LATEST NEWSLETTER

PUBLICATIONS

Top